AI Summary
Consuming moderate amounts of coffee and caffeine may lower the risk of developing multiple cardiometabolic diseases, such as type 2 diabetes, coronary heart disease, and stroke. Research suggests that regular coffee intake, particularly at moderate levels, is associated with a lower risk of new-onset cardiometabolic conditions. This protective effect could be crucial in preventing the development of multiple cardiometabolic diseases, a growing public health concern. The study recommends consuming three cups of coffee or 200-300 mg of caffeine per day to reduce the risk of cardiometabolic multimorbidity. Compared to non-consumers, individuals consuming moderate coffee or caffeine amounts had a significantly lower risk for developing these conditions.
Consuming moderate amounts of coffee and caffeine regularly may offer a protective effect against developing multiple cardiometabolic diseases, including type 2 diabetes, coronary heart disease and stroke, according to new research published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.
Researchers found that regular coffee or caffeine intake, especially at moderate levels, was associated with a lower risk of new-onset cardiometabolic multimorbidity (CM), which refers to the coexistence of at least two cardiometabolic diseases.
The prevalence of individuals with multiple cardiometabolic diseases, or CM, is becoming an increasing public health concern as populations age around the world, notes the study.
Coffee and caffeine consumption could play an important protective role in almost all phases of CM development, researchers found.
Consuming three cups of coffee, or 200-300 mg caffeine, per day might help to reduce the risk of developing cardiometabolic multimorbidity in individuals without any cardiometabolic disease.”
Chaofu Ke, M.D., Ph.D., study’s lead author of the Department of Epidemiology and Biostatistics, School of Public Health at Suzhou Medical College of Soochow University, in Suzhou, China
The study found that compared with non-consumers or consumers of less than 100mg caffeine per day, consumers of moderate amount of coffee (3 drinks per day) or caffeine (200-300 mg per day) had the lowest risk for new-onset CM.
The study found that compared with non-consumers or consumers of less than 100mg caffeine per day, consumers of moderate amount of coffee (3 drinks per day) or caffeine (200-300 mg per day) had a 48.1% or 40.7% reduced